How Novartis’s Businesses Have Been Performing

Novartis’s business segments

Novartis’s (NVS) business is separated into three segments:

  • Innovative Medicines, the prescription medicines business
  • Sandoz, the generics business
  • Alcon, the eye care business

How Novartis’s Businesses Have Been Performing

The above chart compares revenues of Novartis’s segments since the first quarter of 2017.

Innovative Medicines

The Innovative Medicines segment includes products from Novartis Pharmaceuticals and Novartis Oncology.

The Innovative Medicines segment reported revenue of ~$8.9 billion in the second quarter, a 10% rise compared to its revenue of ~$8.1 billion in the second quarter of 2017. At constant exchange rates, the company’s pharmaceutical revenue rose 6%, and its oncology revenue rose 10% in the quarter.

The segment reported a 12-percentage-point rise in volumes and a 1-percentage-point negative impact of prices. It also saw a 3-percentage-point negative impact of generic competition in the quarter.

Sandoz

Sandoz reported nearly flat revenue at ~$2.46 billion in the second quarter of 2018 compared to $2.45 billion in the second quarter of 2017.

Sandoz reported a 7-percentage-point rise in volumes offset by a 9-percentage-point negative impact of prices in the quarter.

Alcon

Alcon reported revenue of ~$1.8 billion in the second quarter, a 7% rise compared to revenue of ~$1.7 billion in the second quarter of 2017.

At constant exchange rates, the segment’s surgical products reported an 8% rise in revenue, while vision care products reported a 1% rise in the quarter.

The Invesco BLDRS Developed Markets 100 ADR ETF (ADRD) holds 5.4% of its total investment Novartis, 2.5% in AstraZeneca (AZN), 1.9% in Novo Nordisk (NVO), and 2.5% in GlaxoSmithKline (GSK).